Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Ligelizumab
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
1 trial -
Linagliptin
Boehringer Ingelheim
Diabetes Mellitus, Type 2
3 trials -
Linvoseltamab
Regeneron UK Limited
Relapsed and/or Refractory Multiple Myeloma (RRMM)
1 trial -
Linvoseltamab
Regeneron UK Limited
Multiple Myeloma (MM)
1 trial -
Linvoseltamab
Regeneron UK Limited
High Risk Smoldering Multiple Myeloma (HR-SMM)
1 trial -
Linvoseltamab
Regeneron UK Limited
Relapsed Refractory Multiple Myeloma (RRMM)
2 trials -
Linvoseltamab
Regeneron UK Limited
Multiple Myeloma
6 trials -
Liposomal bupivacaine
Pacira Ireland Limited
Surgery
1 trial -
Lisdexamfetamine dimesylate
Takeda
Binge Eating Disorder
2 trials -
Lokelma 5 g powder for oral suspension, Lokelma 10 g powder for oral suspension
The George Institute
Hyperkalemia in patients with chronic kidney disease
1 trial -
Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin
Ascendis Pharma Endocrinology Division A/S
Turner Syndrome (TS), idiopathic short stature (ISS), short stature homeobox containing gene deficiency (SHOX-D), small for gestational age (SGA)
1 trial -
Loncastuximab Tesirine
ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma
1 trial -
Lucentis 10 mg/ml solution for injection, Ranibizumab
CuraTeQ Biologics s.r.o
wet macula degeneration
1 trial -
Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets
The George Institute
Patients with a histological diagnosis of p53abn HREC, treated with curative intent, after surgery (hysterectomy and bilateral salpingooophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases
1 trial -
Lynparza 100 mg film-coated tablets, Sodium Chloride Intravenous Infusion BP 0.9% w/v Solution for Infusion (not authorised), Placebo film-coated tablet (Not Authorised), Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, BEVACIZUMAB
AstraZeneca AB
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer
1 trial -
Lynparza 150 mg film-coated tablets, IBRANCE 125 mg hard capsules, Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Tabrecta 200 mg film-coated tablets, Daurismo 100 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, Tabrecta 150 mg film-coated tablets, Lytgobi 4 mg film-coated tablets, Mekinist 2 mg film-coated tablets, IBRANCE 100 mg hard capsules, Tyverb 250 mg film-coated tablets, Tafinlar 75 mg hard capsules, Zykadia 150 mg hard capsules, IBRANCE 7
The George Institute
Unresectable locally advanced and/or metastatic soft-tissue sarcoma
1 trial -
Lynparza 150 mg film-coated tablets, PACLITAXEL , CARBOPLATIN , GEMCITABINE , DOXORUBICIN , Lynparza 100 mg film-coated tablets, CISPLATIN , BEVACIZUMAB
Fondazione Telethon ETS
Recurrent ovarian cancer
1 trial -
MC0518, EVEROLIMUS, MYCOPHENOLIC ACID , ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)
Medac Gesellschaft fuer klinische Spezialpraeparate mbH
Steroid refractory Acute Graft versus host Disease
1 trial -
MEDI4736 Placebo, DURVALUMAB
CERO THERAPEUTICS HOLDINGS, INC.
Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients
1 trial -
MEDROXYPROGESTERONE , Opevesostat, EXEMESTANE , LETROZOLE , MEGESTROL , FLUDROCORTISONE , TAMOXIFEN , FULVESTRANT , HYDROCORTISONE , DEXAMETHASONE
Merck Sharp and Dohme
Breast cancer, Ovarian cancer, Endometrial cancer
1 trial -
MEP
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
METFORMIN
Pari Pharma GmbH
Type 2 Diabetes complete remission after bariatric surgery under antidiabetic drug
1 trial -
METFORMINE ARROW LAB 1000 mg, comprimé pelliculé sécable, Placebo de metformine Arrow Lab 1000 mg - Composition: Cellulose microcristalline; Lactose monohydraté; Stéarate de magnésium (vegetable origin); Opadry TM 07F28588; Eau purifiée
Pari Pharma GmbH
Vascular calcification and type 1 diabetes
1 trial -
METHOTREXATE, METHOTREXATE, DESOXIMETASONE, TACROLIMUS, placebo, Acidum folicum Léčiva 10 mg obalené tablety, FOLIC ACID
Medac Gesellschaft fuer klinische Spezialpraeparate mbH
moderate to severe atopic dermatitis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources